European regulators have recommended expanding use of the IL-23 inhibitor Skyrizi to treat moderate-to-severe plaque psoriasis in children aged 6 years or older who require systemic therapy.

April 27 (Reuters) - Oruka Therapeutics said on Monday that interim results showed its experimental drug helped clear psoriasis within 16 weeks, meeting the main goal of a mid-stage study and sending ...

Oruka Therapeutics shares gained after the company announced positive results for its Phase 2a trial of a psoriasis treatment. The stock jumped 22% to $84 in premarket trading Monday. Through Friday's ...

Switching to guselkumab for psoriasis treatment was associated with the greatest rate of treatment persistence when compared with other therapies.

Oruka Therapeutics (ORKA) earns a Strong Buy on positive ORKA-001 phase 2a psoriasis data; watch key 2026–2027 catalysts and ...

Across a number of studies, researchers have found that following a Mediterranean-style diet—which includes olive oil and ...

A long-acting injectable treatment for plaque psoriasis helped 63% of patients achieve complete skin clearance in a clinical ...

Oruka Therapeutics’ long-acting plaque psoriasis candidate cleared the skin of 63.5% of patients in a phase 2a trial, leading ...

ORKA-001 also met secondary endpoints at 16 weeks, and updated data support the potential for once-yearly dosing ...

A therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the ...

For many patients without a primary care provider, a dermatologist may be the only healthcare professional who can counsel ...

Icotyde (icotrokinra) has been approved by the US FDA to treat moderate-to-severe plaque psoriasis (PsO) in both adults and ...